ABVC

ABVC BioPharma, Inc. NASDAQ Listed Nov 10, 2004

Healthcare ·Biotechnology ·US · abvcpharma.com

$1.80

Mkt Cap $26.1M

52w Low $0.88 20.0% of range 52w High $5.48

50d MA $1.25 200d MA $1.93

P/E (TTM) —

EV/EBITDA —

P/B 3.1x

Debt/Equity 0.3x

ROE -71.2%

P/FCF -14.0x

RSI (14) 79.50

ATR (14) $0.14

Beta 0.38

50d MA $1.25

200d MA $1.93

Avg Volume 151.9K

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.

SIC Code

2834

CIK (SEC)

1173313

Phone

510 668 0881

44370 Old Warm Springs Boulevard · Fremont, CA 94538 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 3, 2026	AMC	—	-0.12	—	1.42	+0.7%	+2.1%	-2.8%	-5.0%	+9.0%	+0.0%	—
Oct 31, 2025	AMC	—	-0.05	—	2.80	+0.0%	+5.7%	-4.7%	+2.5%	-1.7%	+2.5%	—
Aug 13, 2025	AMC	—	-0.13	—	2.97	+1.0%	+2.4%	+8.6%	-5.2%	-8.9%	+8.4%	—
Apr 30, 2025	AMC	—	-0.06	—	1.06	-2.8%	-2.8%	+1.9%	+6.7%	+2.7%	+10.4%	—
Apr 15, 2025	AMC	—	0.04	—	0.90	-0.6%	+8.4%	-11.9%	+2.1%	-4.7%	+5.3%	—
Nov 14, 2024	AMC	—	-0.02	—	0.55	+5.3%	-9.3%	+2.0%	+2.9%	+8.0%	-3.0%	—
Aug 14, 2024	AMC	—	-0.09	—	0.75	+2.7%	-5.2%	-7.3%	+5.5%	+6.2%	-0.9%	—
Mar 13, 2024	AMC	-0.50	-0.35	+30.0%	1.23	+0.8%	-2.4%	-2.5%	-0.9%	-3.4%	-4.5%	—
Nov 15, 2023	AMC	-0.40	-0.82	-105.0%	1.25	-1.6%	+27.2%	-2.5%	+9.0%	+5.3%	+5.1%	—
Aug 14, 2023	AMC	-0.60	-0.68	-13.3%	1.87	+0.5%	+2.1%	+1.6%	-7.2%	+3.9%	+7.0%	—
May 15, 2023	AMC	-0.50	-0.60	-20.0%	7.80	-7.7%	-10.9%	+10.8%	-4.8%	-0.4%	-5.5%	—
Mar 31, 2023	AMC	-1.90	-1.50	+21.1%	6.40	+0.0%	+0.3%	+0.0%	-2.8%	+3.8%	+2.9%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Nov 16	Maxim Group	Downgrade	Buy → Hold	—	$7.17	$7.26	+1.3%	+8.8%	-1.3%	-3.6%	-5.4%	+7.5%

Data updated apr 24, 2026 10:20am · Source: financialmodelingprep.com